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AbstrAct:
Specific changes in gene expression during cancer initiation should enable discovery 
of biomarkers for risk assessment, early detection and targets for chemoprevention. 
It has been previously demonstrated that altered mRNA and proteome signatures of 
morphologically normal cells bearing a single inherited “hit” in a tumor suppressor 
gene parallel many changes observed in the corresponding sporadic cancer. 
Here, we report on the global gene expression profile of morphologically normal, 
cultured primary breast epithelial and stromal cells from Li-Fraumeni syndrome 
(LFS)  TP53  mutation  carriers.  Our  analyses  identified  multiple  changes  in  gene 
expression in both morphologically normal breast epithelial and stromal cells 
associated with TP53 haploinsufficiency, as well as interlocking pathways.  Notably, 
a dysregulated p53 signaling pathway was readily detectable. Pharmacological 
intervention with the p53 rescue compounds CP-31398 and PRIMA-1 provided 
further evidence in support of the central role of p53 in affecting these changes 
in LFS cells and treatment for this cancer. Because loss of signaling mediated by 
TP53 is associated with the development and survival of many human tumors, 
identification  of  gene  expression  profiles  in  morphologically  normal  cells  that 
carry “one-hit” p53 mutations may reveal novel biomarkers, enabling the 
discovery of potential targets for chemoprevention of sporadic tumors as well. 
IntroductIon
Germline  TP53 mutations occur in Li-Fraumeni 
syndrome (LFS), a rare, inherited autosomal dominant 
disorder which is characterized by early onset of multiple 
primary tumors [1]. These malignancies include sarcomas, 
breast cancers, glioblastomas, adrenal cortical tumors, 
colon cancers, lung cancers, and leukemias, among others 
[1-2]. Mutations in the TP53 tumor suppressor gene are 
found in 70% of classic LFS families and 30% of LFS-
like kindreds [3-4]. Germline mutations occur in one 
allele and, as predicted by the classic Knudson two-hit Oncotarget 2010; 1:  405 - 422 406 www.impactjournals.com/oncotarget
hypothesis, the second allele is somatically inactivated 
through mutation, deletion or epigenetic repression (i.e., 
loss of heterozygosity, LOH) in LFS mutation carrier 
cancers [4-5]. The two-hit hypothesis has been validated 
recently  through  recent  findings  of  one-hit  effects  in 
cancer [6-11].
Clinical criteria for diagnosis are established for 
classic LFS. These criteria include individuals with 
an  early  onset  sarcoma,  a  first  degree  relative  with 
cancer  before  age  45  and  another  first-degree  relative 
with sarcoma at any age or any cancer before age 45 
[1]. Furthermore, the National Comprehensive Cancer 
Network (NCCN) guidelines provide recommendations 
for screening LFS family members for early detection. 
These recommendations include annual dermatological 
and neurological exam, colonoscopy every 2-5 years, 
breast  MRI  beginning  at  age  20,  and  family  specific 
studies (NCCN; www.nccn.org).
Despite the significant susceptibility to cancer, breast 
cancer in particular, and risk of early death in LFS families, 
there are currently no molecular approaches for risk 
assessment or early detection, nor cancer chemoprevention 
strategies to help LFS families. Molecular diagnosis 
of LFS is complicated by the fact that almost all LFS-
associated TP53 mutations are missense [12-13]. Missense 
variants are difficult to classify distinctly as deleterious 
or benign due to the high level of evidence required for 
clinical diagnosis. Clinicians are often reluctant to make 
a diagnosis of LFS because of the inherent ambiguity 
of classifying missense variants. Therefore, molecular 
diagnostics that use different approaches to confirm and 
validate diagnosis of LFS in individuals who carry TP53 
missense mutations are needed. These diagnostics are 
also useful in patients in whom no identifiable mutation 
is found (i.e., false negatives). Because tumors arise in 
multiple stages, there are several potential steps at which 
tumor initiation or progression could be targeted to 
prevent malignancies. 
Here, we describe whole genome expression 
profiling of primary epithelial and stromal cells from LFS 
patients with defined germline TP53 mutations and paired 
normal cell samples processed in parallel. We demonstrate 
that the morphologically normal epithelial and stromal 
cells from LFS mutation carriers display altered gene 
expression profiles in a cell type-specific manner. Notably, 
in  breast  epithelial  and  stromal  fibroblast  cells  with 
TP53  haploinsufficiency,  a  dysregulated  p53  signaling 
pathway was readily detectable using gene expression 
profiling  technology.  The  abnormal  alterations  seen  in 
LFS cells are distinct from previous FAP and BRCA1-
2 specific gene expression changes [8, 10]. While gene 
expression profiling is currently used to analyze breast 
cancers and assess recurrence risk and chemosensitivity 
(such as with Oncotype Dx or Mammaprint), it has not 
yet been applied to the detection of morphologically 
normal, but cancer susceptible, tissues. Our study shows 
that gene expression profiling is able to distinguish TP53 
haploinsufficient breast epithelial and stromal cells from 
matched tissue from an individual with wild-type TP53. 
These data suggest that genomic profiling can help define 
molecular targets for chemoprevention and biomarkers of 
breast cancer risk impacted by early alteration in TP53. 
Significantly, pharmacological intervention with the p53 
rescue  compounds  CP-31398  and  PRIMA-1  provided 
further evidence in support of the central role of p53 
in affecting these changes in LFS cells and treatment 
for this cancer. These studies will provide more precise 
molecular markers specific for early TP53 alterations and 
enable mechanism-based early detection and personalized 
prevention strategies for cancer.
results
Gene  expression  profiling  of  single-hit  LFS 
epithelial and stromal cell cultures. 
Morphologically normal, breast-derived epithelial 
and stromal cells were established from TP53-
haploinsufficient and mutation-negative (TP53 wild-type, 
WT) individuals. LFS is a rare disorder and the amount of 
breast tissue available from affected individuals in which 
to derive breast cell lines is therefore limited. One LFS 
sample (patient 50) was derived from the noninvolved 
tissue of a 31year-old female undergoing surgery for 
breast cancer. Patient 50 came from a family in which 
breast cancer and the TP53 mutations were prevalent 
through at least three generations [14]. The other LFS (or 
LFS-like) sample (patient IUSM) was derived from the 
benign breast tissue of a 29-year old Caucasian female 
undergoing surgery for non-invasive ductal carcinoma 
and bilateral Paget’s disease of the nipples. Patient IUSM 
also had a maternal aunt with bilateral breast cancer in 
her 30’s and a male sibling with osteogenic sarcoma of 
a leg at age 13 who later died of a brain tumor at age 
19. LFS patient 50 contained a heterozygous missense 
mutation in the DNA binding domain of TP53 that affects 
the conformation of the p53, while the other sample 
(patient IUSM) had a heterozygous frameshift mutation in 
the proline-rich domain of TP53, resulting in a truncated 
protein. Four biologically independent replicates of these 
cells, and four biologically independent replicates from 
an age-matched female with no history of breast cancer, 
were used to analyze whole genome expression profiles of 
LFS heterozygous mutation-carrying and wild-type cells. 
Class comparison analyses (i.e., TP53 vs. WT) revealed 
notable changes in gene expression, suggesting that 
germline heterozygous TP53 mutations significantly alter 
the expression profiles of both primary epithelial cells and 
fibroblasts (Figure 1; Tables 1-3; Supplemental Figure 1; 
Supplemental Data File 1). The genes most differentially Oncotarget 2010; 1:  405 - 422 www.impactjournals.com/oncotarget 407
Gene 
Symbol Description Fold 
Change p-value
Genes upregulated in LFS vs. WT epithelial cells
ZNF415 Zinc finger protein 415 10.411 5.96E-05
BIRC3 Baculoviral IAP repeat-containing 3 9.628 3.13E-03
NMES1 Normal mucosa of esophagus specific 1 9.509 1.43E-02
Transcribed locus 9.431 1.35E-04
DNCI2 Dynein, cytoplasmic, intermediate polypeptide 2 7.322 5.94E-07
EGR3 Early growth response 3 7.059 5.23E-03
GPNMB Glycoprotein (transmembrane) nmb 7.044 5.80E-04
ZNF506 zinc finger protein 506 7.005 8.66E-10
MICB MHC class I polypeptide-related sequence B 6.998 1.23E-04
EMP2 epithelial membrane protein 2 6.809 6.28E-03
Genes downregulated in LFS vs. WT epithelial cells
MYEF2 Myelin expression factor 2 -7.196 8.10E-06
DOC1 Downregulated in ovarian cancer 1 -8.229 1.25E-05
C7orf10 Chromosome 7 open reading frame 10 -10.124 1.86E-08
C13orf18 Chromosome 13 open reading frame 18 -10.519 6.49E-07
GHR Growth hormone receptor -11.471 7.45E-11
HOXB7 Homeo  -14.978 7.37E-08
ANGPTL4 Angiopoietin-like 4 -18.426 1.81E-09
SLC38A5 Solute carrier family 38, member 5 -18.469 2.92E-04
NEFL Neurofilament, light polypeptide 68kDa -19.512 8.72E-06
XG
Xg blood group (pseudoautosomal boundary-divided on the X 
chromosome) -65.958 7.36E-05
Genes upregulated in LFS vs. WT stromal cells
TM4SF1 Transmembrane 4 superfamily member 1 31.899 1.27E-05
TM4SF1 Transmembrane 4 superfamily member 1 29.644 5.12E-06
TM4SF1 Transmembrane 4 superfamily member 1 25.646 2.62E-05
TM4SF13 Transmembrane 4 superfamily member 13 12.675 2.54E-04
FABP5 Fatty acid binding protein 5 (psoriasis-associated) 10.582 3.50E-03
G0S2 Putative lymphocyte G0/G1 switch gene 10.572 3.60E-03
PTGS1
Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase 
and cyclooxygenase) 9.926 1.67E-05
RAMP RA-regulated nuclear matrix-associated protein 9.155 1.13E-04
RAD51AP1 RAD51 associated protein 1 9.132 9.19E-03
FLJ31340 Hypothetical protein FLJ31340 9.020 2.03E-02
Genes downregulated in LFS vs. WT stromal cells
ARHGAP26 Rho GTPase activating protein 26 -6.532 6.63E-08
CCND2 Cyclin D2 -6.615 1.17E-02
RGC32 Response gene to complement 32 -7.036 2.60E-16
PSG4 Pregnancy specific beta-1-glycoprotein 4 -7.149 1.09E-15
Transcribed locus -7.179 4.97E-10
RDH10 Retinol dehydrogenase 10 (all-trans) -7.779 8.74E-12
STEAP2 Six transmembrane epithelial antigen of prostate 2 -8.158 1.67E-21
COPl CARD only protein -10.944 2.92E-08
GPM6B Glycoprotein M6B -11.299 8.01E-06
GPM6B Glycoprotein M6B -11.772 1.42E-06
Table 1. List of the top differentially regulated genes between both of the LFS and WT cells in epithelial and stromal tissue types.Oncotarget 2010; 1:  405 - 422 www.impactjournals.com/oncotarget 408
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Figure 1:  Gene expression patterns between TP53 heterozygous and WT breast epithelial and stromal cells.  A) Principal 
component analyses (PCA) of samples.  Spheres depict breast epithelial samples (BR), while triangles depict stromal samples.  Red objects 
represent LFS patient 50 samples, blue objects represent samples derived from IUSM-LFS patient, and green objects represent normal/WT 
samples.  B) PCA of LFS-50 compared to LFS-IUSM samples.  C) Supervised heat-map with gene expression patterns of the top 100 genes 
noting clusters differentiating diseased vs. non-diseased samples. The bars above the panel depict sample clusters; top: tissue/sample type (left 
to right: BR, breast epithelial; STR, stromal); middle: ID/cell line (left to right: NA, normal/WT; 50, patient 50; IUSM, cells derived from 
IUSM patient); bottom: genotype/phenotype (left to right: N, normal/WT; LF, Li-Fraumeni syndrome).  The different colored bars on the left 
of the panel represent different clusters of biological processes.  Gene expression variation is depicted by color (red, up-regulated; blue, down-
regulated; gray, no significant change).  The genes and Gene Ontology of Biological Processes are listed in Supplemental Data. Oncotarget 2010; 1:  405 - 422 409 www.impactjournals.com/oncotarget
regulated in LFS vs. WT cells for both epithelial and 
fibroblast cell types are shown in Table 1.
Principal component analyses (PCA) of the global 
expression profiles revealed that each sample set clustered 
together (Figure 1A). The stromal and epithelial samples 
were clearly positioned in two different coordinates from 
each other (Figure 1A). Interestingly, the LFS patient 
50 epithelial samples were positioned separately from 
the other LFS and WT samples (Figure 1B). The large 
difference in the nature of the mutation and position of 
the LFS-50 samples from the other (LFS-IUSM) samples 
could affect the severity of haploinsufficiency of the TP53 
mutation. Hierarchical clustering of the top 100 genes from 
the arrays revealed distinct clusters differentiating disease 
genotype, the stromal and epithelial samples, as well as 
LFS and WT samples (Figure 1C; Supplemental Figure 1; 
Supplemental Data File1). The epithelial samples revealed 
more distinct clustering of the top 100 genes between the 
LFS and WT individuals than the stromal samples. 
To  confirm  the  results  of  the  gene  expression 
microarray, qRT-PCR validation was performed on the 
RNA samples used for the initial array. A full list of the 
validated primers can be found in Supplemental Table 
1. The genes examined represent a number of different 
functions in p53 signaling, cell proliferation (cell cycle 
regulation), and cell survival (apoptosis) as detected 
from the gene expression data and Ingenuity Pathway 
Analysis described below. The expressions of genes 
in LFS samples by qRT-PCR were observed to have 
consistent dysregulation between normal and LFS cells, 
and were similar to those changes by gene microarray 
(Supplemental Table 2). 
Gene  expression  profiles  of  single-hit  LFS 
epithelial  cells  compared  to  WT  epithelial  cell 
cultures.
Further  data  mining  revealed  highly  significant 
differences for epithelial cell comparisons. One of the 
most dramatic differences in gene expression between 
both of the LFS epithelial samples and WT epithelial cells 
was in the Xg blood group protein (-66 fold; p<0.0001; 
Table 1), a cell surface antigen [15]. In addition, there was 
a significant upregulation of BIRC3 (9.6 fold; p<0.003) 
in  the  LFS  cells  (Table  1).  Furthermore,  a  significant 
upregulation of transcription factor EP300 (p300; 3.1 
fold; P=7.5 x 10-7; FDR 9.29 x 10-5; see Supplemental 
Data Files 2 and 3) was observed for the LFS epithelial 
cells.  Notably, Table 1 shows that two of the most highly 
up-regulated genes with extreme statistical significance 
(p<0.00001) were the zinc finger-containing transcription 
factors ZN415 (10.4 fold change; P=5.96 x 10-5; FDR 2.16 
x 10-3) and ZN506 (7.0 fold change; P=8.66 x 10-10; FDR 
7.22 x 10-7). These are zinc finger-containing transcription 
factors and, similar to p300, their upregulation is likely to 
reflect a compensatory effect of TP53 haploinsufficiency 
to regulate critical TP53 targets. Similarly notable was 
the downregulation of multiple members of the HOXB7 
signal transduction pathway (Table 1), which is important 
for maintenance of cell differentiation [16]. There is 
evidence that HOXB7 is regulated by the extracellular 
matrix in mammary epithelial cell cultures [17]. The 
downregulation of HOXB7 in both of the LFS epithelial 
cells, compared to WT, suggests an important role for the 
surrounding tissue and stroma for epithelial cell growth 
regulation in LFS patients. 
Using Ingenuity Pathway Analysis (IPA) with FDR 
of 10% and fold change cut-off of +/- 2, we evaluated the 
interaction and functional importance of the signaling 
pathways  involving  genes  significantly  dysregulated 
in both of the LFS epithelial cells compared to WT 
epithelial cells. The top ten canonical pathways that were 
significantly modulated between LFS and WT breast cells 
are depicted in Figure 2A. Molecules associated within 
these pathways are listed in Table 2. Significant pathways 
in the epithelial LFS vs. WT sample set included Wnt/β-
catenin, tight junction, cell cycle, and oxidative stress 
signaling pathways. Noteworthy in these pathway analyses 
was a highly significant representation of the IPA-defined 
TP53 signaling pathway in the epithelial (-LogP value 
of 2.30) samples (Figure 2A; Supplemental Data File 4). 
Specific perturbations included the TP53 transcriptional 
network targets CDKN2A, CCND2, THBS1, C12ORF5, 
CTNNB1, and EP300 (Table 2). Gene interaction networks 
analysis of the 472 genes differentially expressed in the 
TP53 haploinsufficient yet morphologically normal breast 
epithelial cell cultures revealed two significant networks 
relative to WT breast epithelial cells (Figure 3). Several 
genes were down-regulated in the ERK network (Figure 
3A) and upregulated in the IL1B/p300/BIRC3 (Figure 
3B) in LFS breast epithelial cells relative to WT breast 
epithelial cells. 
Gene expression profiles of single-hit LFS stromal 
cells compared to WT stromal cell cultures.
An important strength of this study was the inclusion 
of a stromal cell array set to analyze gene expression 
profile changes between initiated LFS and WT cells. Thus, 
in addition to examining the breast epithelial cells of LFS 
vs. WT individuals, we were also able to identify gene 
expression alterations for the stromal fibroblast cells that 
may indicate changes in the breast microenvironment. 
These changes could predispose the p53-haploinsufficient 
epithelial cells to transformation. In examining the 
stromal cells from LFS vs. WT individuals (Table 1), 
there were striking differences in gene expression. The 
top four genes upregulated in LFS stromal cells were 
TM4SF1 and TM4SF13. The gene products are members 
of the tetraspanin family of cell surface proteins. These 
proteins have been associated with cancer and are also Oncotarget 2010; 1:  405 - 422 www.impactjournals.com/oncotarget 410
Figure 3: Ingenuity pathway analysis of genes differentially regulated in LFS vs. WT epithelial cells. Functional pathway 
analysis by IPA of ERK (A) and IL1B/p300/BIRC3 (B) genes and their interaction nodes in LFS breast epithelial cells relative to WT breast 
epithelial cells. Gene expression variation by at least 2-fold is depicted by color (red, up-regulated; green, down-regulated; gray, no significant 
change). Oncotarget 2010; 1:  405 - 422 www.impactjournals.com/oncotarget 411
Ingenuity Canonical 
Pathways Molecules
Epithelial Cells
Wnt/β-catenin Signaling CSNK1E,CDKN2A,CSNK1G1,PPP2R2B,TGFB2,PPP2R2C,KREMEN1,DKK1,CTNNB1,EP300
Tight Junction Signaling MYLK,MPDZ,CLDN12,PPP2R2B,PVRL3,TGFB2,PPP2R2C,ACTG2 (includes EG:72),CTNNB1
Cycle: G1/S Checkpoint 
Regulation CDKN2A,CCND2,NRG1,CDK6,TGFB2
Aryl Hydrocarbon Receptor 
Signaling CDKN2A,CCND2,ALDH1A3,NQO1,CDK6,TGFB2,IL1B,EP300
Coagulation System PROS1,SERPINA1,PLAU,F3
NRF2-mediated Oxidative 
Stress Response FTL,NQO1,DNAJC1,AOX1,ACTG2 (includes EG:72),FKBP5,TXNRD1,EP300,EPHX1
p53 Signaling CDKN2A,CCND2,THBS1,C12ORF5,CTNNB1,EP300
Acute Phase Response 
Signaling FTL,FN1,IL1RN,IL1B,C5,SERPINA1,STAT3,IL1RAP
Selenoamino Acid 
Metabolism SEPHS1,GGT1,AHCY
Eicosanoid Signaling AKR1C3,PNPLA3,PTGS2,GGT1
Stromal Cells
Aryl Hydrocarbon Receptor 
Signaling
TP53,GSTM1,CCNE2,POLA1,GSTM3 (includes 
EG:2947),NQO1,BAX,CHEK1,CCNA2,GSTM2,CCND2,ALDH1A3,CDKN1A,GSTM4,IL1B,DHFR,CDK2,M
CM7
Role of BRCA1 in DNA 
Damage Response TP53,RAD51,RFC4,MSH2,CDKN1A,MSH6,RFC2,RBL1,RFC5,CHEK1
Pyrimidine Metabolism
TYMS,PRIM1,NME5,DCK,POLE2,POLA1,RRM2B,RRM2,REV3L,RFC5,CTPS,NME7,RRM1,POLD3,NP,
POLA2,TK1
p53 Signaling
TP53,CCNG1,GADD45B,CCND2,RRM2B,CDKN1A,TNFRSF10B,BAX,CDK2,BIRC5,CHEK1,DRAM 
(includes EG:55332)
Cycle: G1/S Checkpoint 
Regulation TP53,CCNE2,CCND2,HDAC8,SUV39H1,CDKN1A,NRG1,RBL1,CDK2
Glutathione Metabolism GPX3,GSTM1,TRHDE,GSTM2,GSTM3 (includes EG:2947),GPX1,GSTM4,G6PD,H6PD,GCLM
Purine Metabolism
PRIM1,ATP1B1,NME5,DCK,DDX39,POLE2,POLA1,RRM2B,RRM2,REV3L,RFC5,NME7,RRM1,RAD51,
PRPS2,POLD3,PRPS1,NP,ADA,POLA2,PDE5A,ENPP2,AOX1,PPAT
Pentose Phosphate 
Pathway PRPS2,PRPS1,TKT,G6PD,H6PD,ALDOC
NRF2-mediated Oxidative 
Stress Response
GSTM1,DNAJC9,GSTM3 (includes 
EG:2947),NQO1,GSTM2,RRAS2,SOD2,CAT,GSTM4,SQSTM1,AOX1,GCLM,ACTC1,PRKD1,FTH1
Histidine Metabolism PRPS2,PRPS1,ALDH1A3,FTSJ1,MAOA
Table 2:  List of molecules within the top ten gene networks generated from IPA and significantly modulated between the 
LFS and WT breast epithelial or stromal cells.Oncotarget 2010; 1:  405 - 422 412 www.impactjournals.com/oncotarget
known  as  tumor  associated  antigens  [18].  Cyclin D2 
(CCND2), which is often lost in breast cancer due to 
promoter  hypermethylation  [19-20],  was  significantly 
downregulated in LFS stromal cells, compared to WT 
(6.6 fold; p<0.012), suggesting a marked dysregulation 
of the cell cycle in these stromal cells. Though cyclin 
D2 is involved in promoting the G1-S transition of the 
cell cycle, Meyyappan et al. [21] showed that this protein 
can also be growth-arresting, which may suggest why 
it was downregulated in breast stromal cells (Table 1). 
A similar yet less dramatic downregulation (1.9 fold; 
p<0.001) of cyclin D2 was observed in the LFS epithelial 
cells compared to WT epithelial cells (see Supplemental 
Data File 2). These findings indicate that loss of cyclin 
D2 is a very early event in cancer progression in the TP53 
heterozygous breast epithelial and stromal cells. Another 
gene that was dysregulated in the LFS fibroblasts was 
the G0S2 gene (10.5 fold upregulated; p<0.004; Table 1), 
which is involved in the G0 to G1 transition, leading to cell 
cycle activation [22]. The changes in expression of both 
Cyclin D2 and G0S2 indicate that the p53-haploinsufficient 
stromal cells have a substantial disruption of normal cell 
cycle progression, which suggests a role for these cells in 
breast tissue growth and therefore on cancer predisposition 
of LFS patients. 
As expected, the stromal fibroblast gene expression 
signature of TP53 haploinsufficiency was comprised of 
not only similar, but additional genes than epithelial cells 
in the IPA-defined TP53 signaling pathway (Figure 2B, 
Table 2). In addition, significant pathways in the stromal 
LFS vs. WT sample set included DNA damage response 
and amino acid metabolism. These data demonstrate and 
confirm in two different tissues that the genes involved in 
the TP53 pathway (-Log P value of 3.24) are especially 
susceptible to reductions in TP53 transcriptional activity. 
To  corroborate  this  interesting  result  of  significant 
network pathways, we performed IPA of stromal 
cells from LFS patients and matched normal subjects. 
Gene interaction networks analysis of the 1093 genes 
differentially  expressed  in  the  TP53  haploinsufficient, 
morphologically normal breast stromal cell cultures 
revealed two significant networks relative to WT breast 
stromal cells. These networks included the IL1B/CDK2 
(Figure 4A) and TP53 (Figure 4B) nodes and their gene 
interactions. Interestingly, while IL1B was downregulated 
in the epithelial comparison set (Figure 3B) IL1B was 
upregulated in the stromal comparison set (Figure 4A).
Comparing the gene interactions of the epithelial 
and stromal LFS cell cultures to the WT samples, a 
significant interaction network contained ERK. Epithelial 
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Figure 2: Top gene networks generated from IPA and significantly modulated (log p-value) between both of the LFS cells 
and WT cells.  A) Top ten networks significantly modulated between LFS and WT breast epithelial cells.  B) Top ten networks significantly 
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Figure 4: Ingenuity pathway analysis of genes differentially regulated in LFS vs. WT stromal cells. Functional pathway analysis 
by IPA of IL1B/CDK2 (A) and TP53 (B) gene pathways and their interaction nodes in LFS breast stromal cells relative to WT breast stromal 
cells. Oncotarget 2010; 1:  405 - 422 www.impactjournals.com/oncotarget 414
Gene tItle Gene sYMbol P-VAlue FDR
FoLDChAnGE
(50/IUSM)
CYTOCHROME P450, FAMILY 1, SUBFAMILY B, POLYPEPTIDE 1 CYP1B1 5.15E-09 0.000112 -16.2203
PROTEIN-L-ISOASPARTATE (D-ASPARTATE) O-
METHYLTRANSFERASE DOMAIN CONTAINING 1 PCMTD1 3.63E-08 0.000290 -7.33201
CHURCHILL DOMAIN CONTAINING 1 CHURC1 3.82E-07 0.001748 3.2
SMU-1 SUPPRESSOR OF MEC-8 AND UNC-52 HOMOLOG (C. 
ELEGANS) SMU1 4.60E-07 0.001748 -1.81118
DISCOIDIN DOMAIN RECEPTOR TYROSINE KINASE 2 DDR2 7.62E-07 0.001869 -6.44987
LYR MOTIF CONTAINING 5 LYRM5 9.57E-07 0.001869 -2.96636
GLUCOCORTICOID INDUCED TRANSCRIPT 1 GLCCI1 9.88E-07 0.001869 -3.69182
KTEL (LYS-TYR-GLU-LEU) CONTAINING 1 KTELC1 1.14E-06 0.001869 -2.9365
PROTEIN KINASE, CAMP-DEPENDENT, CATALYTIC, BETA PRKACB 1.19E-06 0.001869 -1.84956
ROD1 REGULATOR OF DIFFERENTIATION 1 (S. POMBE) ROD1 1.24E-06 0.001869 1.94034
TRANSMEMBRANE PROTEIN 157 TMEM157 1.53E-06 0.001869 -2.16878
ZINC FINGER PROTEIN 655 ZNF655 1.64E-06 0.001869 -3.33563
INOSITOL HEXAPHOSPHATE KINASE 2 IHPK2 1.67E-06 0.001869 -2.662
REPLICATION INITIATOR 1 REPIN1 1.73E-06 0.001869 -14.9282
ZINC FINGER PROTEIN 430 ZNF430 1.80E-06 0.001869 -2.65347
GLUTATHIONE PEROXIDASE 7 GPX7 1.91E-06 0.001869 -5.19146
TRANSCRIPTION ELONGATION FACTOR A (SII)-LIKE 1 TCEAL1 1.92E-06 0.001869 -3.0577
CYTOCHROME P450, FAMILY 1, SUBFAMILY B, POLYPEPTIDE 1 CYP1B1 2.05E-06 0.001869 -13.6735
CARBOXYLESTERASE 2 (INTESTINE, LIVER) CES2 2.18E-06 0.001869 -5.24574
HYPOTHETICAL PROTEIN LOC339400 LOC339400 2.25E-06 0.001869 -18.8473
CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 6-LIKE CNOT6L 2.27E-06 0.001869 -2.04665
ZINC FINGER PROTEIN 605 ZNF605 2.31E-06 0.001869 -2.70276
CHROMOSOME 9 OPEN READING FRAME 61 C9ORF61 2.41E-06 0.001869 -8.82731
TP53 REGULATED INHIBITOR OF APOPTOSIS 1 TRIAP1 2.43E-06 0.001869 -2.65011
ZINC FINGER HOMEOBOX 4 ZFHX4 2.56E-06 0.001869 -4.08673
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Ingenuity Canonical 
Pathways
Molecules
Epithelial Cells
Wnt/β-catenin Signaling CSNK1E,CDKN2A,CSNK1G1,PPP2R2B,TGFB2,PPP2R2C,KREMEN1,DKK1,CTNNB1,EP300
Tight Junction Signaling MYLK,MPDZ,CLDN12,PPP2R2B,PVRL3,TGFB2,PPP2R2C,ACTG2 (includes EG:72),CTNNB1
Cycle: G1/S Checkpoint 
Regulation CDKN2A,CCND2,NRG1,CDK6,TGFB2
Aryl Hydrocarbon Receptor 
Signaling CDKN2A,CCND2,ALDH1A3,NQO1,CDK6,TGFB2,IL1B,EP300
Coagulation System PROS1,SERPINA1,PLAU,F3
NRF2-mediated Oxidative 
Stress Response FTL,NQO1,DNAJC1,AOX1,ACTG2 (includes EG:72),FKBP5,TXNRD1,EP300,EPHX1
p53 Signaling CDKN2A,CCND2,THBS1,C12ORF5,CTNNB1,EP300
Acute Phase Response 
Signaling FTL,FN1,IL1RN,IL1B,C5,SERPINA1,STAT3,IL1RAP
Selenoamino Acid 
Metabolism SEPHS1,GGT1,AHCY
Eicosanoid Signaling AKR1C3,PNPLA3,PTGS2,GGT1
Stromal Cells
Aryl Hydrocarbon Receptor 
Signaling
TP53,GSTM1,CCNE2,POLA1,GSTM3 (includes 
EG:2947),NQO1,BAX,CHEK1,CCNA2,GSTM2,CCND2,ALDH1A3,CDKN1A,GSTM4,IL1B,DHFR,CDK2,M
CM7
Role of BRCA1 in DNA 
Damage Response TP53,RAD51,RFC4,MSH2,CDKN1A,MSH6,RFC2,RBL1,RFC5,CHEK1
Pyrimidine Metabolism
TYMS,PRIM1,NME5,DCK,POLE2,POLA1,RRM2B,RRM2,REV3L,RFC5,CTPS,NME7,RRM1,POLD3,NP,
POLA2,TK1
p53 Signaling
TP53,CCNG1,GADD45B,CCND2,RRM2B,CDKN1A,TNFRSF10B,BAX,CDK2,BIRC5,CHEK1,DRAM 
(includes EG:55332)
Cycle: G1/S Checkpoint 
Regulation TP53,CCNE2,CCND2,HDAC8,SUV39H1,CDKN1A,NRG1,RBL1,CDK2
Glutathione Metabolism GPX3,GSTM1,TRHDE,GSTM2,GSTM3 (includes EG:2947),GPX1,GSTM4,G6PD,H6PD,GCLM
Purine Metabolism
PRIM1,ATP1B1,NME5,DCK,DDX39,POLE2,POLA1,RRM2B,RRM2,REV3L,RFC5,NME7,RRM1,RAD51,
PRPS2,POLD3,PRPS1,NP,ADA,POLA2,PDE5A,ENPP2,AOX1,PPAT
Pentose Phosphate 
Pathway PRPS2,PRPS1,TKT,G6PD,H6PD,ALDOC
NRF2-mediated Oxidative 
Stress Response
GSTM1,DNAJC9,GSTM3 (includes 
EG:2947),NQO1,GSTM2,RRAS2,SOD2,CAT,GSTM4,SQSTM1,AOX1,GCLM,ACTC1,PRKD1,FTH1
Histidine Metabolism PRPS2,PRPS1,ALDH1A3,FTSJ1,MAOA
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to mesenchymal transition (EMT) is an important pathway 
through which epithelial cells can progress to malignancy. 
Increased ERK signaling is one important pathway that 
contributes to EMT [23]. The genes within the ERK nodal 
network were depicted as mainly down-regulated and 
included SULF1, MFGE8, LOXL1, LTBP1, and COL4A 
(Suppl Figure 2A; Suppl Table 3). Also notable was 
the presence of alpha integrins and extracellular matrix 
proteins (e.g., laminins) that interact with other genes 
within  this  network.  Furthermore,  a  second  significant 
gene interaction network was the NF-κB interaction node 
(Suppl Figure 2B) where the upregulation of BIRC3 and a 
downregulation of GOS2 were also present. 
Differences in gene expression profiles between 
two LFS cell lines with different TP53 mutations
When IPA was performed to distinguish comparisons 
of patient 50 vs. normal/WT epithelial samples as well as 
patient IUSM vs. WT epithelial samples, the top three 
canonical pathways were the same between the two sets 
of  comparisons.  Importantly,  while  the  specific  genes 
whose expression was altered were different between 
the two LFS patient samples (Figure 1 and Tables 3-4; 
Supplemental Figure 1C), the top networks and canonical 
pathways from IPA were similar.   Thus, each LFS patient 
cells achieved essentially the same pathway alterations 
with slightly different granular details compared to WT 
samples (Figure 5). In summary, while the heterozygous 
p53 mutations in these two patients were different, the IPA 
results suggest that the phenotype of these cells derived 
from LFS or LFS-like patients are similar at the cellular 
level.  
Treatment  of  LFS  breast  epithelial  cells  with 
TP53 rescue drugs restores WT gene expression 
of altered genes. 
Since breast epithelial cells from LFS patient 50 
contain a missense mutation in TP53 that affects its protein 
conformation, we tested whether restoring p53 function 
by pharmacological agents will modulate expression of 
p53- and cell cycle-related genes (Supplemental Table 1). 
Cells were treated for 72 hours with 10 µM of PRIMA-1, 
CP-31398, or a combination of both, and compared to 
untreated cells. This dose was previously shown to induce 
senescence and reduce anchorage-independent growth 
on soft agar of tumorigenic LFS breast epithelial cells 
(Herbert et al., manuscript in preparation). Breast epithelial 
cells from LFS patient IUSM contain a frameshift 
mutation in the proline-rich domain of TP53 and were not 
affected by treatment with the p53 rescue agents (data not 
shown). The combination of both p53 reactivating agents 
inhibited proliferation of LFS epithelial cells compared 
to untreated cells and to a greater extent than either drug 
alone (Figure 6A). Real-time RT-PCR was performed on 
the treated cells compared to untreated cells (Figure 6B). 
The genes investigated were the same p53/cell cycle gene 
sets as those investigated for the microarray validation of 
the LFS samples versus non-LFS samples (Suppl. Table 
1).  Of  significant  note,  treatment  of  the  LFS  samples 
with the p53 rescue agents resulted in a reduction in 
the expression of the anti-apoptotic gene BIRC3 in LFS 
samples compared to untreated samples. In this case, 
combination  of  PRIMA-1  and  CP-31398  resulted  in  a 
significant reduction in BIRC3 expression compared to 
either drug alone (P<0.001). As expected, treatment of 
LFS breast epithelial cells with PRIMA-1 or CP-31398 
resulted in a significant increase in BAX gene expression 
A
B
Figure  5.    Ingenuity  Pathway Analysis  (IPA)  for  LFS-50  vs. 
WT Epithelial Cells and the Comparison of LFS-IUSM vs. WT 
Epithelial Cells.  Functional pathway analysis by IPA of LFS-50 vs. 
WT Epithelial Cells (A) and LFS-IUSM vs. WT Epithelial Cells (B) 
gene comparisons and their interaction nodes. Oncotarget 2010; 1:  405 - 422 417 www.impactjournals.com/oncotarget
(P<0.001), a pro-apoptotic gene, compared to untreated 
cells. Although combination of both agents did not result 
in an additive or synergistic fold increase in BAX, it was 
still greater than untreated samples, suggesting a possible 
saturation point of the pro-apoptotic gene. Treatment of 
LFS epithelial cells with PRIMA-1 restored the expression 
of IL1B (P=0.02); however, CP31398 nor the combination 
of both agents did not result in a statistically significant 
change compared to untreated samples. Furthermore, the 
combination of both agents actually was antagonistic to 
that of PRIMA-1 treatment alone (Figure 6B). 
dIscussIon
In this study, we examined morphologically normal 
breast epithelial and stromal cells derived from patients 
(one classical LFS, the other with similar LFS clinical 
criteria as described in Mouchawar et al., ref. 24) with 
heterozygous mutations in TP53 (“one-hit”) compared to 
cells derived from control (wild-type TP53) individuals. 
We observed significant differences in gene expression 
profiles between the wild-type cells and LFS cells for both 
cell types. Many of the differentially regulated genes were 
involved in signaling pathways known to be dysregulated 
in cancer, breast cancer in particular, including cell cycle 
regulation, apoptosis, and the WNT signaling pathway. 
Together, activation of these aberrant pathways is likely 
to contribute to cancer initiation in normal tissue of LFS 
patients.
The  TP53 tumor suppressor gene responds to a 
variety of cellular stressors, including DNA damage, 
hypoxia, metabolic stress, and oncogene activation. 
Under these conditions, the p53 protein is stabilized 
and initiates a transcriptional program resulting in DNA 
repair, cell-cycle arrest, senescence, or apoptosis. The 
specific program triggered is heterogeneous and depends 
on the type and strength of the incoming stress signals 
and the cellular context in which the response is executed. 
Although mutations affecting p53 are present in virtually 
all human cancers, “stress-induced” non-mutational 
activation of p53 occur very early in cancer progression 
and may precede and perhaps facilitate mutational 
activation associated with p53 [25-28]. In addition, recent 
evidence on early-onset breast cancers that did not meet 
the clinical criteria of LFS suggested that germline TP53 
mutations play a larger role in disease progression than 
previously considered [24]. 
Several additional players in stress response, 
apoptosis, and cell signaling shown here were noted 
for  significant  changes  in  gene  expression  and  gene 
interaction networks. For example, we found changes in 
gene expression and networks for BAX and IL1B which 
are pro-apoptotic and pro-inflammatory response genes, 
respectively [29-30]. In addition, clustering analyses 
between LFS and WT samples highlighted WISP3 which 
is an anti-inflammatory response gene which help prolong 
cell growth and survival [31]. Other significant genes in the 
analyses included CDK2, CDKN1A (p21), and CHEK1, all 
regulators of the cell cycle [32-34]. BIRC3, also known as 
cIAP2, plays an important role in promoting cell survival 
and inhibiting apoptosis [35]. The increased expression 
of BIRC3 found in our analyses of LFS breast epithelial 
and stromal cells, and the normalization of expression 
with TP53 conformational rescue drugs, are consistent 
with an important role for BIRC3 anti-apoptotic signals 
in LFS initiated cells, and with recent findings that BIRC3 
can drive tumorigenesis on a p53-deficient background 
in mouse osteosarcoma [36]. Importantly, the presence 
of the BIRC3 signature suggests a potentially relevant 
early  detection  biomarker  for  TP53  haploinsufficiency 
0
20
40
60
80
100
120
P
e
r
c
e
n
t
 
g
r
o
w
t
h
 
(
v
s
.
 
U
T
 
c
e
l
l
s
)
B
A
0
0.5
1
1.5
2
2.5
F
o
l
d
 
C
h
a
n
g
e
IL1B Expression
0
0.5
1
1.5
2
2.5
F
o
l
d
 
C
h
a
n
g
e
BAX Expression
0
0.5
1
1.5
2
2.5
F
o
l
d
 
C
h
a
n
g
e
BIRC3 Expression
0
0.5
1
1.5
2
2.5
F
o
l
d
 
C
h
a
n
g
e
CDK2 Expression
*
*
***
*** *
***
*
Figure 6.  TP53 rescue agents restore expression of dysregulated 
genes in LFS breast epithelial cells.  A) Effects on LFS-50 breast 
epithelial cell growth by the p53 rescue agents PRIMA-1 and CP-
31398,  compared  to  untreated  control  (normalized  to  100%).    B) 
Analysis of top genes (via qRT-PCR) from LFS microarray/p53 
network of LFS epithelial cells (LFS-50 breast epithelial cells) treated 
with 10 µM PRIMA-1, CP-31398, or combination of both.  Data is 
average of at least two independent experiments, with three replicates 
per treatment group, plus standard error.  Statistical significance was 
determined by a two-tailed Students’ t-test (MS Excel) where P<0.05 
was considered significant (*, P<0.05; **, P<0.01; ***, P<0.001).Oncotarget 2010; 1:  405 - 422 418 www.impactjournals.com/oncotarget
that could facilitate cellular transformation in LFS pre-
neoplastic cells, and be a potential chemopreventative 
drug target.
Also notable in our analyses was the upregulation 
of  EP300 (p300) in LFS samples compared to WT 
samples. p300 is a transcription factor in a number of 
pathways, including as a coactivator that competes 
with the coactivator CBP for TP53 binding and TP53 
signaling [37]. At the same time, CBP mRNA levels were 
not  significantly  changed  in  these  analyses  (p>0.05). 
The upregulation of p300 transactivation likely reflects 
a compensatory effect of cells to stimulate TP53-p300 
critical transcriptional genes in response to TP53 
haploinsufficiency in breast epithelial and stromal cells.   
Furthermore, several zinc finger-containing transcription 
factors were also upregulated in our analyses and, similar 
to p300, their upregulation may suggest a compensatory 
effect of TP53 haploinsufficiency to regulate critical TP53 
targets. 
An important strength of our study was the inclusion 
of a stromal cell array set, in addition to breast epithelial 
cells, to analyze gene expression profile changes between 
LFS (heterozygous mutation in TP53) and WT stromal 
cells. Gene expression changes in the stromal compartment 
of one-hit LFS samples compared to wild-type samples 
may indicate changes in the breast microenvironment that 
play  a  role  in  cancer  progression,  including  influences 
on epithelial to mesenchymal transition (EMT). Our 
IPA analyses shows that IL1B (interleukin-1β  or IL-
1β) represents a significant gene network and signaling 
pathway. We showed that IL1B was upregulated in the 
stromal LFS samples compared to WT samples. Because 
IL-1β is a key pro-inflammatory secreted cytokine that is 
cleaved by caspase-1 [38], it may be useful as a biomarker 
for morphologically normal, but molecularly abnormal, 
breast tissue. Additionally, these data form the basis for 
future studies that examine whether inhibition of IL-1β 
signaling plays a mechanistic role in preventing cancer 
progression  and  EMT  in  TP53-haploinsufficient  cells. 
While most reports on IL1B are related to H. pylori 
infection and gastric cancer [39 for review] these studies 
have suggested that IL-1β is a critical link in inflammation 
as it leads to cancer [40]. Therefore, it will be important to 
examine the impact of IL1B expression as a biomarker of 
increased breast cancer risk in LFS patients.
Recently, p53 has been shown to function in aging 
and senescence through the regulation of mTOR, a 
key player in aging, metabolism and autophagy [41-
44].  DNA  repair  deficiency  diseases  are  classified  as 
part of the group of metabolic syndromes. While there 
are no known relationships between LFS patients and 
metabolic syndrome symptoms (J. Fraumeni, personal 
communication), there is a current clinical trial on 
the “Role of p53 Gene in Metabolism Regulation in 
Patients with Li-Fraumeni Syndrome” (ClinicalTrials.
gov  Identifier:  NCT00406445).  Furthermore,  in  our 
study of one-hit TP53 early passage, logarithmically 
growing cell lines, mTOR or associated genes were not 
significantly  altered  compared  to  the  wild-type  cells 
(stromal or epithelial). However, as the aging stroma 
has been shown to promote carcinogenesis [41, 45], the 
alterations in pathways involved with aging metabolism 
and inflammation observed in our study on one-hit TP53 
cells may support other studies demonstrating the role 
of p53 in these processes [41, 46-47]. In addition, these 
findings may offer an explanation, in part, for the early 
incidence of cancer in Li-Fraumeni syndrome families.
Genetically restoring p53 function alone, without 
additional  treatments,  has  been  shown  to  be  sufficient 
to  induce  regression  of  advanced  tumors  [48-51]. 
Significantly,  pharmacologic  intervention  by  small 
molecules that rescue mutant p53 or activate wild-type 
protein can suppress or delay growth of established 
tumors in animals [52, 26]. Furthermore, we demonstrated 
that expression of a subset of these genes can be 
reverted to normal, wild-type individual levels by TP53 
conformational modulators such as PRIMA-1 or CP-
31398. In particular, the normalization of elevated BIRC3 
expression levels in a morphologically normal LFS cell 
line with these drugs suggests BIRC3 is a particularly 
attractive  chemopreventative  target.  This  defined  gene 
expression panel can be used as potential biomarkers for 
TP53 conformation-modulating small molecules in the 
chemoprevention of TP53 mutation causing malignancies, 
both in LFS and in the general population, as TP53 
mutations are common. 
Families with Li-Fraumeni Syndrome are at 
high risk of dying from a variety of malignancies. 
The diversity of cancer sites makes intensive cancer 
surveillance particularly important for LFS mutation 
carriers. Individuals with BRCA1/2 or Lynch syndrome 
gene mutations have improved outcomes after diagnosis 
with intensive cancer surveillance. Individuals with 
LFS  are  even  more  likely  to  benefit  from  intensive 
cancer surveillance. Diagnosis of LFS is often difficult 
because many of the TP53 mutations are missense, which 
requires clinicians to have a very high level of evidence 
to make a positive diagnosis. It is therefore important 
to  find  distinctions  between  LFS  and  normal  tissue  to 
facilitate early diagnosis and targeted chemoprevention. 
Our  data  defined  a  potential  molecular  diagnostic  tool 
that can be used to increase the depth of molecular 
testing used to confirm that an individual carries a LFS-
causing pathological TP53 missense mutation. Our data 
also defined sets of genes in two different tissues that 
are especially susceptible to small decreases, or “one-
hit” effects, in TP53 levels [9]. Significantly, our study 
suggests that the nature and site of mutations in the p53 
underwrite the severity of abnormal molecular changes 
in  the  context  of  the  LFS  syndrome.  These  findings 
are supported by the recent studies which showed that 
subtle variations in Pten copy number determine cancer Oncotarget 2010; 1:  405 - 422 419 www.impactjournals.com/oncotarget
susceptibility in mouse models [11]. Further studies will 
be important to test whether these genes may be useful for 
distinguishing between LFS and sporadic TP53-deficient 
tissues from normal tissues in individuals at risk of cancer. 
In summary, because breast cancer incidence in LFS 
cohorts is very high [53], comparing abnormal pathways 
in LFS with those abnormal pathways in other inherited 
deficiencies,  such  as  BRCA1/2  or  Cowden  syndrome 
which also predispose individuals to breast cancer, in 
addition to examining sporadic breast cancer, might 
further our understanding of treatment for breast cancer.  
MATERIALS AnD METhoDS
Ethics Statement
Informed consent was obtained to collect patient 
tissue and this research was conducted according to 
the ethical standards and principles expressed in the 
Declaration of Helsinki. Ethical approval was obtained 
from the local research ethics committee in compliance 
with HIPAA privacy regulations as well as Institutional 
Review Board regulations governing patient-oriented 
research (IRB protocol #0403-87).
Patient  Details,  Tissue  Procurement,  and  Cell 
Culture
An LFS-like series was derived in 2006 from benign 
breast tissue of a 29-year old white female with non-
invasive ductal carcinoma and bilateral Paget’s disease 
of the nipples undergoing surgery at Indiana University 
School of Medicine (IUSM). Human breast tissue was 
minced or enzymatically digested with collagenase I, plated 
onto culture dishes and cultured in defined media to select 
for human mammary epithelial (HME) or stromal (HMS) 
cells as previously described [14]. A heterozygous TP53 
12141delG germline frameshift mutation was identified 
in both the epithelial and stromal cells by conventional 
sequencing of exons 2-11 and intron-exon boundaries 
(Herbert, unpublished observations). The HME/HMS50 
cell series (a generous gift by J.W. Shay) was derived 
from a 31-year-old Li-Fraumeni syndrome (LFS) patient’s 
benign breast tissue (containing a heterozygous germline 
mutation at codon 133 in exon 5 in one of the two alleles 
of the TP53 gene (Met to Thr [M133T]) that affects wild-
type p53 protein conformation) as previously characterized 
[14]. Normal human mammary epithelial and stromal 
cells (a generous gift by J.W. Shay) derived from an age-
matched female with no history of cancer were cultured 
as previously described [14]. The cell lines have been 
tested for TP53 mutations by conventional sequencing, 
as well as characterization of cell surface markers and 
mycoplasma by immunocytology or thermocycler, within 
the last year and authenticated to have the same mutations, 
characteristics, and were mycoplasma-free, respectively. 
HME cells were cultured in modified basal medium 
171 (Cascade Biologics, Portland, OR) supplemented 
with 0.5% bovine pituitary extract (Hammond Cell 
Technologies), 100 µg/ml epidermal growth factor 
(Invitrogen), 10 µg/ml insulin, 1 µg/ml hydrocortisone, 
10  µg/ml transferrin (Sigma-Aldrich, St. Louis, MO). 
Medium was changed every 2-3 days. HMS cells were 
cultured as described [14]. All cells were tested at the 
same log phase of cell growth and at similar passages. 
RnA Extraction and Preparation
Four biologically independent samples for each 
experimental group were collected for RNA, according to 
the Center for Medical Genomics guidelines [54]. Total 
RNA was prepared from cultured cells using the Qiagen 
RNeasy kit. All RNA samples were confirmed to have 
an A260/280 ratio of >1.8 by spectrophotometer and gel 
electrophoresis. Total RNA was diluted to a concentration 
of 1 µg/µl and 10 µg was given the Center for Medical 
Genomics for microarray processing. RNA integrity 
was further validated on an Agilent Bioanalyzer. All the 
samples showed distinct peaks corresponding to intact 
28S and 18S ribosomal RNAs and therefore were included 
in the analysis.
Microarray Processing and Analysis
Microarray processing was performed at the 
Center for Medical Genomics at the Indiana University 
School of Medicine. Preparation of cDNA and cRNA, 
as well as labeling was carried out according to the 
protocols recommended by Affymetrix in the GeneChip® 
Expression Analysis Technical Manual (Affymetrix, Santa 
Clara, CA). Arrays (HGU133 plus 2.0) were hybridized for 
17h at 42oC. The arrays were washed and stained protocol 
by fluidics stations controlled by GCOS software using 
the standard Affymetrix protocol. The microarrays were 
scanned using a dedicated Model 3000 scanner controlled 
by GCOS software. The average intensity on each array 
was normalized by global scaling to a target intensity 
of 1000. Data were extracted using the Affymetrix 
Microarray Suite 5 (MAS5) algorithm and exported for 
analysis. Expression Data were deposited into the Gene 
Expression Omnibus (GSE accession #GSE23994).
The MAS5 data were filtered to eliminate any gene 
that was not called present in at least 50% of the samples 
in at least one group [55]. Data was log base 2 transformed 
and ANOVA (Analysis of Variance) was performed using 
the log transformed data. False discovery rate (FDR) was 
calculated using the Benjamini and Hochberg method 
[54]. Partek Genomics Suite software (Partek, Inc. St. 
Louis, MO) was used for hierarchical clustering. Log Oncotarget 2010; 1:  405 - 422 420 www.impactjournals.com/oncotarget
transformed data for the top 200 genes, as determined by 
p-value from the ANOVA, were clustered using Pearson’s 
Dissimilarity as the distance measure and average linkage. 
The arrays were left unclustered. 
Ingenuity Pathway Analysis of Gene Expression 
Arrays
Ingenuity Pathway Analysis was executed on a subset 
of the original microarray data. Microarray output includes 
a value (‘P’, ‘M’, or ‘A’) for each transcript describing the 
confidence of detection. We filtered out transcripts that did 
not show sufficient read status. We required that a gene 
be present in at least half of the samples in at least one 
of four groups within the experiment: epithelial diseased, 
epithelial normal, stromal diseased or stromal normal 
[55]. This limited the original 54675 mRNAs to 21684.
The analysis for this study was generated using 
Partek® software (Partek Inc., St. Louis, MO, USA) 
to calculate p-value and fold change for each logical 
comparison (epithelial diseased versus epithelial non-
diseased, stromal diseased versus stromal non-diseased, 
and the differences between the epithelial comparison 
versus the stromal comparison). The p-value was 
calculated using a mixed-effect model with disease and 
cell type as two factors (or ‘fixed effects’) and cell line as a 
‘random effect’. Next, we approximated a false discovery 
rate (FDR) score for each protein using the Benjamini-
Hochberg method [56-57]. Finally, we limited the data set 
for IPA analysis to genes having a FDR score less than or 
equal to 0.1 (meaning an overall FDR for the entire data 
set of 10%) and an absolute fold change greater than or 
equal to 2 (meaning fold change must be greater than 2 or 
less than -2). At this point we separated the data set into 
logical analysis groups.
The molecular interactions among differentially-
expressed  genes  (FDR≤0.1)  were  investigated  using 
Ingenuity Pathway Analysis (IPA 6.1; Ingenuity systems, 
www.ingenuity.com; Mountain View, CA). Each gene 
identifier was mapped to its corresponding gene in the 
Ingenuity Pathway Knowledge Base (IPKB). These genes 
were overlaid onto a global network developed from the 
information contained in the IPKB. Networks of these 
genes, defined as the reflection of all interactions of a given 
gene defined in the literature, were then algorithmically 
generated based on their connectivity. 
Real-Time  RT-PCR  validation  of  microarray 
analysis
Validation of the microarray results were conducted 
by real-time RT-PCR using primers to a subset of genes 
from the microarray (Supplemental Table 1). Analysis 
was performed twice using triplicate repeats of RNA from 
each cell type and disease state. Analysis was performed 
using a 7500 PCR system and the corresponding 7500 SDS 
software (Applied Biosystems, Foster City, CA). For each 
gene, the threshold cycle number (Ct) was determined for 
all samples and individual sample Ct’s were normalized 
to  those  of  the  housekeeping  gene  β-actin.  Relative 
gene  expression  changes  were  quantified  by  exporting 
raw Ct values to MS Excel for ΔΔCt analysis and fold-
change (2^(-ΔΔCt)) compared to WT or untreated control 
samples. 
Treatment with TP53 rescue agents
LFS breast epithelial cells were plated in 6-well 
dishes  in  the  absence  or  presence  of  CP-31398  (N’-
{2-[2-(4-Methoxy-phenyl)-vinyl]-quinazolin-4-yl}-
N,N-dimethyl-propane-1,3-diamine hydrochloride) or 
PRIMA-1 (p53  reactivation and induction of massive 
apoptosis; 2,2-Bis(Hydroxymethyl)-3-Quinuclidinone) 
at different concentrations compared to untreated and 
solvent controls. CP-31398 and PRIMA-1 were supplied 
by DCP Repository/Fisher BioServices (Germantown, 
MD) and were dissolved in DMSO at 10 mM stock 
concentrations. A preliminary cytotoxicity test was 
performed to determine the highest nontoxic dose to be 
tested as well as EC50 (GraphPad Prism analysis). After 
72 hr of treatment, cells were collected and used for gene 
expression analyses by real-time PCR described above. 
Statistical  significance  was  determined  by  a  two-tailed 
Students’ t-test where P<0.05 was considered significant.
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